Chronic Imatinib (>3 Years) Therapy after Complete Resection of Primary, High-Risk Gastrointestinal Stromal Tumor (GIST) Is Associated with Low Recurrence

Authors :: Ronald P. DeMatteo
Mary Louise Keohan
William D. Tap
Michael J. Cavnar
Vinod P. Balachandran
Ping Chi
Source :: Journal of the American College of Surgeons. 223:e44
Publication Year :: 2016
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2016.

Subjects :: Oncology
medicine.medical_specialty
GiST
business.industry
Imatinib
Complete resection
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
Surgery
030212 general & internal medicine
High Risk Gastrointestinal Stromal Tumor
business
medicine.drug

Full Text Access

Tools